None listed
Conditions
Interventions
During a 30 minute washout period post-extubation, patients will be titrated to receive a fraction of oxygen (FiO2) at a flow rate of 30 lpm. At the end of this period an arterial blood gas sample will be taken. Patients will then be randomised to receive either FMO or HFNO. The FiO2 and flow rate will remain the same. At the end of 30 minutes an ABG will be taken. Patients will then crossover to receive the other mode for 30 minutes with an ABG taken at the end of the period.
The FMO group wil
During a 30 minute washout period post-extubation, patients will be titrated to receive a fraction of oxygen (FiO2) at a flow rate of 30 lpm. At the end of this period an arterial blood gas sample will be taken. Patients will then be randomised to receive either FMO or HFNO. The FiO2 and flow rate will remain the same. At the end of 30 minutes an ABG will be taken. Patients will then crossover to receive the other mode for 30 minutes with an ABG taken at the end of the period. The FMO group will have oxygen supplied via a Hudson Face Mask and a Fisher & Paykel Healthcare MR850 humidifier. The HFNO group will have oxygen supplied via a Fisher & Paykel Healthcare MR880 humidification system.
Sponsors
Fisher and Paykel Healthcare
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Patients meeting extubation criteria whose families provide consent and later give delayed consent.
Exclusion criteria
Patients who do not consent; patients with DNR order.
Outcome results
None listed